Review
Medicine, Research & Experimental
Jacobo Kerbel, Amayrani Cano-Zaragoza, Rodrigo Espinosa-Dorado, Keren-Enid Garcia de la Torre, Moises Mercado
Summary: National registries are valuable tools to investigate rare conditions like acromegaly, providing insights into epidemiology, clinical presentation, diagnosis, treatment outcomes, and mortality. While single-center studies are more homogeneous, they are often limited by small sample sizes and lack statistical power.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Luigi Maione, Cristina Albrici, Solange Grunenwald, Celine Mouly, Vincenzo Cimino, Anne-Lise Lecoq, Jean Claude Souberbielle, Philippe Caron, Philippe Chanson
Summary: This study compared the serum IGF-I dynamics and variability in patients treated with SRLs, surgically cured patients, and healthy controls. The results showed that IGF-I decreased significantly at Day 7 and Day 14 after injection in SRL-treated patients, but remained stable in cured patients and healthy controls. In addition, SRL-treated patients had higher IGF-I variability, especially in nonoptimally controlled patients. The measurement at the farthest distance from SRL injection was the best predictor of optimal disease control.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Malgorzata Rolla, Aleksandra Jawiarczyk-Przybylowska, Jowita Halupczok-Zyla, Marcin Kaluzny, Bogumil M. Konopka, Izabela Bloniecka, Grzegorz Zielinski, Marek Bolanowski
Summary: Acromegaly patients, predominantly female, commonly suffer from complications such as metabolic disorders, cardiovascular diseases, and endocrine disorders. A majority of patients demonstrate a coexistence of cardiac, metabolic, and endocrine disturbances, with a small percentage being disease-free in these main groups.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: The study investigated predictors of response to Pegvisomant and Pasireotide LAR in acromegaly patients, finding that factors such as tumor extension, Ki67-Li levels, and IGF-I levels may impact treatment efficacy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Mirela-Diana Ilie, Antoine Tabarin, Alexandre Vasiljevic, Jean-Francois Bonneville, Lucile Moreau-Grange, Franck Schillo, Brigitte Delemer, Anne Barlier, Dominique Figarella-Branger, Segolene Bisot-Locard, Alexandre Santos, Philippe Chanson, Gerald Raverot
Summary: This study aimed to explore the factors related to SRLs in the treatment of acromegaly and confirmed that SST2A and adenoma granularity are good predictors of response to octreotide. In addition, the optimization of MRI sequences is important for using T2WSI as a predictor of treatment response.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
E. Sala, G. Carosi, G. Del Sindaco, R. Mungari, A. Cremaschi, A. L. Serban, C. L. Ronchi, E. Ferrante, M. Arosio, G. Mantovani
Summary: A subset of well-controlled acromegalic patients can successfully withdraw from SAs, challenging the concept that medical therapy is a lifelong requirement.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2021)
Article
Endocrinology & Metabolism
Eva C. Coopmans, Aart J. van der Lely, Sebastian J. C. M. M. Neggers
Summary: Acromegaly is a chronic disorder caused by GH-producing pituitary adenoma. While surgery and medical therapy are standard treatments, some tumors behave aggressively and are resistant to these therapies. In such cases, multimodal therapeutic strategies should be considered.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Biochemistry & Molecular Biology
Joan Gil, Montserrat Marques-Pamies, Elena Valassi, Araceli Garcia-Martinez, Guillermo Serra, Cristina Hostalot, Carmen Fajardo-Montanana, Cristina Carrato, Ignacio Bernabeu, Monica Marazuela, Helena Rodriguez-Lloveras, Rosa Camara, Isabel Salinas, Cristina Lamas, Betina Biagetti, Andreu Simo-Servat, Susan M. Webb, Antonio Pico, Mireia Jorda, Manel Puig-Domingo
Summary: Acromegaly is a condition caused by excessive growth hormone production due to a pituitary tumor. This study examines the relationship between epithelial-mesenchymal transition (EMT) and resistance to somatostatin receptor ligands (SRLs) in GH-producing tumors. The findings suggest that EMT-related gene expression patterns are heterogeneous, which may explain the varying responses to SRLs.
Article
Endocrinology & Metabolism
Lukasz Mizera, Jowita Halupczok-Zyla, Katarzyna Kolackov, Agnieszka Zembska, Jedrzej Grzegrzolka, Diana Jedrzejuk, Marek Bolanowski, Jacek Daroszewski
Summary: The study found that irisin levels were significantly lower in acromegaly patients compared to controls, suggesting impaired hormonal muscle function contributing to metabolic complications in this disorder. On the other hand, myostatin does not appear to play a critical role in regulating muscle mass in acromegaly. Further studies are needed to better understand the relationship between myostatin and growth hormone in acromegaly.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Medicine, General & Internal
Amit Akirov, Hiba Masri-Iraqi, Idit Dotan, Ilan Shimon
Summary: The diagnosis, management, and treatment of acromegaly heavily rely on the levels of serum IGF-1, basal GH, and nadir GH following OGTT. However, these hormone concentrations can be influenced by various factors, leading to discordant levels that may require additional monitoring and data. New standards for GH and IGF-1 provide more accurate tools, but limitations should be considered along with clinical history and imaging studies when evaluating patients with acromegaly.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Endocrinology & Metabolism
Joan Gil, Mireia Jorda, Berta Soldevila, Manel Puig-Domingo
Summary: Epithelial-mesenchymal transition is a dynamic process that plays essential roles in both physiological and pathological processes, particularly in the growth and invasion of pituitary tumors. Studies have shown the association of EMT with resistance to somatostatin receptor ligands in the treatment of acromegaly.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Susan L. Samson, Lisa B. Nachtigall, Maria Fleseriu, Mojca Jensterle, Patrick J. Manning, Atanaska Elenkova, Mark E. Molitch, William H. Ludlam, Gary Patou, Asi Haviv, Nienke R. Biermasz, Andrea Giustina, Christian J. Strasburger, Laurence Kennedy, Shlomo Melmed
Summary: This study reports the long-term durability of therapeutic response in adults with acromegaly receiving oral octreotide capsules (OOC). The results show that patients maintained a biochemical response while receiving OOC and no new adverse events were observed with prolonged OOC exposure.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Monica R. Gadelha, Ana Carolina Gadelha, Leandro Kasuki
Summary: The treatment of acromegaly has advanced significantly in recent decades, but there are still patients who do not respond to current treatments, highlighting the need for improved treatment burden. Fortunately, there are new treatments in development that may enhance treatment efficacy and convenience.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Emmanuelle Kuhn, Philippe Caron, Brigitte Delemer, Isabelle Raingeard, Herve Lefebvre, Gerald Raverot, Christine Cortet-Rudelli, Rachel Desailloud, Clementine Geffroy, Robin Henocque, Yves Brault, Thierry Brue, Philippe Chanson
Summary: The study aimed to define the medical reasons for treating patients with Pegvisomant (PEG) as monotherapy or combined therapy with somatostatin analogs (SAs). Results showed different patterns of treatment based on patient characteristics and response to therapy, with a focus on tumor concern and ease of normalizing IGF-I levels. Overall, the prospect of reducing PEG injection frequency favored the choice of combined therapy in certain cases.